SMYD2 and breast carcinoma: In a previous study, breast cancer cells were 5 times more sensitive to LLY-507 after seven days of treatment compared to three to four days, indicating that at least some of the SMYD2-dependent epigenetic mechanism may be responsible for the proliferation of breast cancer cells.